Chiara Riganti

List of Publications by Year
in descending order

226	10,119	36303	56724
papers	citations	51 h-index	83 g-index

233	233	233	15854
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Consensus guidelines for the detection of immunogenic cell death. OncoImmunology, 2014, 3, e955691.	4.6	686
2	Consensus guidelines for the definition, detection and interpretation of immunogenic cell death. , 2020, 8, e000337.		610
3	The pentose phosphate pathway: An antioxidant defense and a crossroad in tumor cell fate. Free Radical Biology and Medicine, 2012, 53, 421-436.	2.9	334
4	Molecular and Translational Classifications of DAMPs in Immunogenic Cell Death. Frontiers in Immunology, 2015, 6, 588.	4.8	317
5	Zoledronic acid repolarizes tumourâ€associated macrophages and inhibits mammary carcinogenesis by targeting the mevalonate pathway. Journal of Cellular and Molecular Medicine, 2010, 14, 2803-2815.	3.6	228
6	Nitric oxide reverts the resistance to doxorubicin in human colon cancer cells by inhibiting the drug efflux. Cancer Research, 2005, 65, 516-25.	0.9	187
7	Classical Inhibitors of NOX NAD(P)H Oxidases Are Not Specific. Current Drug Metabolism, 2008, 9, 686-696.	1.2	182
8	Diphenyleneiodonium Inhibits the Cell Redox Metabolism and Induces Oxidative Stress. Journal of Biological Chemistry, 2004, 279, 47726-47731.	3.4	169
9	Phospholipids and cholesterol: Inducers of cancer multidrug resistance and therapeutic targets. Drug Resistance Updates, 2020, 49, 100670.	14.4	146
10	HIF-1 activation induces doxorubicin resistance in MCF7 3-D spheroids via P-glycoprotein expression: a potential model of the chemo-resistance of invasive micropapillary carcinoma of the breast. BMC Cancer, 2012, 12, 4.	2.6	142
11	Artemisinin inhibits inducible nitric oxide synthase and nuclear factor NFâ€kB activation. FEBS Letters, 2003, 552, 141-144.	2.8	135
12	Targeting the Warburg effect in cancer cells through ENO1 knockdown rescues oxidative phosphorylation and induces growth arrest. Oncotarget, 2016, 7, 5598-5612.	1.8	118
13	PERK induces resistance to cell death elicited by endoplasmic reticulum stress and chemotherapy. Molecular Cancer, 2017, 16, 91.	19.2	115
14	Artemisinin induces doxorubicin resistance in human colon cancer cells via calciumâ€dependent activation of HIFâ€1Î± and Pâ€glycoprotein overexpression. British Journal of Pharmacology, 2009, 156, 1054-1066.	5.4	111
15	Carbonic anhydrase XII is a new therapeutic target to overcome chemoresistance in cancer cells. Oncotarget, 2015, 6, 6776-6793.	1.8	102
16	Alpha-enolase (ENO1) controls alpha v/beta 3 integrin expression and regulates pancreatic cancer adhesion, invasion, and metastasis. Journal of Hematology and Oncology, 2017, 10, 16.	17.0	101
17	ERK is a Pivotal Player of Chemo-Immune-Resistance in Cancer. International Journal of Molecular Sciences, 2019, 20, 2505.	4.1	98
18	Hypoxia as a driver of resistance to immunotherapy. Drug Resistance Updates, 2021, 59, 100787.	14.4	94

#	Article	IF	Citations
19	Liposome-Encapsulated Doxorubicin Reverses Drug Resistance by Inhibiting P-Glycoprotein in Human Cancer Cells. Molecular Pharmaceutics, 2011, 8, 683-700.	4.6	93
20	Zoledronic Acid Potentiates mTOR Inhibition and Abolishes the Resistance of Osteosarcoma Cells to RAD001 (Everolimus): Pivotal Role of the Prenylation Process. Cancer Research, 2010, 70, 10329-10339.	0.9	92
21	Fluoride Effects: The Two Faces of Janus. Current Medicinal Chemistry, 2010, 17, 2431-2441.	2.4	90
22	Insulin Stimulates Glucose Transport Via Nitric Oxide/Cyclic GMP Pathway in Human Vascular Smooth Muscle Cells. Arteriosclerosis, Thrombosis, and Vascular Biology, 2003, 23, 2215-2221.	2.4	86
23	Omega 3 fatty acids chemosensitize multidrug resistant colon cancer cells by down-regulating cholesterol synthesis and altering detergent resistant membranes composition. Molecular Cancer, 2013, 12, 137.	19.2	84
24	Curcumin-Loaded Solid Lipid Nanoparticles Bypass P-Glycoprotein Mediated Doxorubicin Resistance in Triple Negative Breast Cancer Cells. Pharmaceutics, 2020, 12, 96.	4.5	83
25	Mitochondria-Targeted Doxorubicin: A New Therapeutic Strategy against Doxorubicin-Resistant Osteosarcoma. Molecular Cancer Therapeutics, 2016, 15, 2640-2652.	4.1	82
26	Iron-Loaded Synthetic Chrysotile:â€‰ A New Model Solid for Studying the Role of Iron in Asbestos Toxicity. Chemical Research in Toxicology, 2007, 20, 380-387.	3.3	81
27	Mutant p53-Associated Molecular Mechanisms of ROS Regulation in Cancer Cells. Biomolecules, 2020, 10, 361.	4.0	79
28	Immune Modulation by Zoledronic Acid in Human Myeloma: An Advantageous Cross-Talk between VÎ³9VÎ´2 T Cells, Î±Î² CD8+ T Cells, Regulatory T Cells, and Dendritic Cells. Journal of Immunology, 2011, 187, 1578-1590.	0.8	77
29	Solid Lipid Nanoparticles for Potential Doxorubicin Delivery in Glioblastoma Treatment: Preliminary In Vitro Studies. Journal of Pharmaceutical Sciences, 2014, 103, 2157-2165.	3.3	77
30	Na+/H+ exchanger activity is increased in doxorubicin-resistant human colon cancer cells and its modulation modifies the sensitivity of the cells to doxorubicin. International Journal of Cancer, 2005, 115, 924-929.	5.1	75
31	The NADPH oxidase inhibitor apocynin (acetovanillone) induces oxidative stress. Toxicology and Applied Pharmacology, 2006, 212, 179-187.	2.8	73
32	Hypoxia, endoplasmic reticulum stress and chemoresistance: dangerous liaisons. Journal of Experimental and Clinical Cancer Research, 2021, 40, 28.	8.6	72
33	The association of statins plus LDL receptorâ€targeted liposomeâ€encapsulated doxorubicin increases in vitro drug delivery across bloodâ€“brain barrier cells. British Journal of Pharmacology, 2012, 167, 1431-1447.	5.4	71
34	iNOS activity is necessary for the cytotoxic and immunogenic effects of doxorubicin in human colon cancer cells. Molecular Cancer, 2009, 8, 108.	19.2	70
35	Nanoparticle- and Liposome-carried Drugs: New Strategies for Active Targeting and Drug Delivery Across Blood-brain Barrier. Current Drug Metabolism, 2013, 14, 625-640.	1.2	70
36	Positive-charged solid lipid nanoparticles as paclitaxel drug delivery system in glioblastoma treatment. European Journal of Pharmaceutics and Biopharmaceutics, 2014, 88, 746-758.	4.3	68

#	Article	IF	Citations
37	Bevacizumab loaded solid lipid nanoparticles prepared by the coacervation technique: preliminaryin vitrostudies. Nanotechnology, 2015, 26, 255102.	2.6	65
38	Pleiotropic Effects of Cardioactive Glycosides. Current Medicinal Chemistry, 2011, 18, 872-885.	2.4	64
39	Temozolomide downregulates P-glycoprotein expression in glioblastoma stem cells by interfering with the Wnt3a/glycogen synthase-3 kinase/Â-catenin pathway. Neuro-Oncology, 2013, 15, 1502-1517.	1.2	64
40	Mitochondrial Targeting of Doxorubicin Eliminates Nuclear Effects Associated with Cardiotoxicity. ACS Chemical Biology, 2015, 10, 2007-2015.	3.4	64
41	Activation of Nuclear Factor-Î²B Pathway by Simvastatin and RhoA Silencing Increases Doxorubicin Cytotoxicity in Human Colon Cancer HT29 Cells. Molecular Pharmacology, 2008, 74, 476-484.	2.3	63
42	Modulation of doxorubicin resistance by the glucose-6-phosphate dehydrogenase activity. Biochemical Journal, 2011, 439, 141-149.	3.7	63
43	Nitric Oxide Donor Doxorubicins Accumulate into Doxorubicin-Resistant Human Colon Cancer Cells Inducing Cytotoxicity. ACS Medicinal Chemistry Letters, 2011, 2, 494-497.	2.8	63
44	Mitochondrial-Targeting Nitrooxy-doxorubicin: A New Approach To Overcome Drug Resistance. Molecular Pharmaceutics, 2013, 10, 161-174.	4.6	62
45	Hypoxia Dictates Metabolic Rewiring of Tumors: Implications for Chemoresistance. Cells, 2020, 9, 2598.	4.1	62
46	IGHV unmutated CLL B cells are more prone to spontaneous apoptosis and subject to environmental prosurvival signals than mutated CLL B cells. Leukemia, 2011, 25, 828-837.	7.2	61
47	Folate-targeted liposomal nitrooxy-doxorubicin: An effective tool against P-glycoprotein-positive and folate receptor-positive tumors. Journal of Controlled Release, 2018, 270, 37-52.	9.9	61
48	Crocidolite asbestos inhibits pentose phosphate oxidative pathway and glucose 6-phosphate dehydrogenase activity in human lung epithelial cells. Free Radical Biology and Medicine, 2002, 32, 938-949.	2.9	59
49	Statins revert doxorubicin resistancevia nitric oxide in malignant mesothelioma. International Journal of Cancer, 2006, 119, 17-27.	5.1	58
50	Anergic bone marrow VÎ³9VÎ´2 T cells as early and long-lasting markers of PD-1-targetable microenvironment-induced immune suppression in human myeloma. OncoImmunology, 2015, 4, e1047580.	4.6	58
51	A LDL-masked liposomal-doxorubicin reverses drug resistance in human cancer cells. Journal of Controlled Release, 2011, 149, 196-205.	9.9	57
52	The ATP-binding cassette transporter A1 regulates phosphoantigen release and VÎ³9VÎ´2 T cell activation by dendritic cells. Nature Communications, 2017, 8, 15663.	12.8	57
53	Drug Resistance in Osteosarcoma: Emerging Biomarkers, Therapeutic Targets and Treatment Strategies. Cancers, 2021, 13, 2878.	3.7	56
54	Doxorubicin Induces an Increase of Nitric Oxide Synthesis in Rat Cardiac Cells That Is Inhibited by Iron Supplementation. Toxicology and Applied Pharmacology, 2002, 185, 85-90.	2.8	55

#	Article	IF	Citations
55	Human Î³Î´ <scp>T</scp>â€cell responses in infection and immunotherapy: Common mechanisms, common mediators?. European Journal of Immunology, 2012, 42, 1668-1676.	2.9	53
56	What sustains the multidrug resistance phenotype beyond ABC efflux transporters? Looking beyond the tip of the iceberg. Drug Resistance Updates, 2019, 46, 100643.	14.4	52
57	Dysfunctional Vδ39Vγ2 T cells are negative prognosticators and markers of dysregulated mevalonate pathway activity in chronic lymphocytic leukemia cells. Blood, 2012, 120, 3271-3279.	1.4	51
58	Different cellular responses evoked by natural and stoichiometric synthetic chrysotile asbestos. Toxicology and Applied Pharmacology, 2005, 206, 356-364.	2.8	50
59	RhoA Silencing Reverts the Resistance to Doxorubicin in Human Colon Cancer Cells. Molecular Cancer Research, 2008, 6, 1607-1620.	3.4	50
60	Endoplasmic reticulum-targeting doxorubicin: a new tool effective against doxorubicin-resistant osteosarcoma. Cellular and Molecular Life Sciences, 2019, 76, 609-625.	5.4	50
61	The Cross-Talk between Canonical and Non-Canonical Wnt-Dependent Pathways Regulates P-Glycoprotein Expression in Human Bloodâ€“Brain Barrier Cells. Journal of Cerebral Blood Flow and Metabolism, 2014, 34, 1258-1269.	4.3	49
62	Two repeated low doses of doxorubicin are more effective than a single high dose against tumors overexpressing P-glycoprotein. Cancer Letters, 2015, 360, 219-226.	7.2	49
63	FAM49B, a novel regulator of mitochondrial function and integrity that suppresses tumor metastasis. Oncogene, 2018, 37, 697-709.	5.9	49
64	From mitochondria to healthy aging: The role of branched-chain amino acids treatment: MATeR a randomized study. Clinical Nutrition, 2020, 39, 2080-2091.	5.0	49
65	Zoledronic Acid Restores Doxorubicin Chemosensitivity and Immunogenic Cell Death in Multidrug-Resistant Human Cancer Cells. PLoS ONE, 2013, 8, e60975.	2.5	49
66	Geranylgeraniol prevents the cytotoxic effects of mevastatin in THPâ€1 cells, without decreasing the beneficial effects on cholesterol synthesis. British Journal of Pharmacology, 2009, 158, 1777-1786.	5.4	48
67	Insulin activates hypoxia-inducible factor-1Î± in human and rat vascular smooth muscle cells via phosphatidylinositol-3 kinase and mitogen-activated protein kinase pathways: impairment in insulin resistance owing to defects in insulin signalling. Diabetologia, 2006, 49, 1049-1063.	6.3	47
68	Temozolomide down-regulates P-glycoprotein in human bloodâ€“brain barrier cells by disrupting Wnt3 signaling. Cellular and Molecular Life Sciences, 2014, 71, 499-516.	5.4	46
69	Mutant p53 prevents GAPDH nuclear translocation in pancreatic cancer cells favoring glycolysis and 2-deoxyglucose sensitivity. Biochimica Et Biophysica Acta - Molecular Cell Research, 2018, 1865, 1914-1923.	4.1	45
70	The DNA damage/repair cascade in glioblastoma cell lines after chemotherapeutic agent treatment. International Journal of Oncology, 2015, 46, 2299-2308.	3.3	44
71	Ï‰-3 Long Chain Polyunsaturated Fatty Acids as Sensitizing Agents and Multidrug Resistance Revertants in Cancer Therapy. International Journal of Molecular Sciences, 2017, 18, 2770.	4.1	44
72	H₂S-Donating Doxorubicins May Overcome Cardiotoxicity and Multidrug Resistance. Journal of Medicinal Chemistry, 2016, 59, 4881-4889.	6.4	43

#	Article	IF	Citations
73	Impact of cancer metabolism on therapy resistance â€“ Clinical implications. Drug Resistance Updates, 2021, 59, 100797.	14.4	43
74	The enzymatic activity of 5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase/IMP cyclohydrolase is enhanced by NPM-ALK: new insights in ALK-mediated pathogenesis and the treatment of ALCL. Blood, 2009, 113, 2776-2790.	1.4	42
75	An inhibitory antibody targeting carbonic anhydrase XII abrogates chemoresistance and significantly reduces lung metastases in an orthotopic breast cancer model in vivo. International Journal of Cancer, 2018, 143, 2065-2075.	5.1	42
76	Bromodomain inhibition exerts its therapeutic potential in malignant pleural mesothelioma by promoting immunogenic cell death and changing the tumor immune-environment. OncoImmunology, 2018, 7, e1398874.	4.6	41
77	Potential Diagnostic and Prognostic Role of Microenvironment in Malignant Pleural Mesothelioma. Journal of Thoracic Oncology, 2019, 14, 1458-1471.	1.1	41
78	Hyaluronated liposomes containing H2S-releasing doxorubicin are effective against P-glycoprotein-positive/doxorubicin-resistant osteosarcoma cells and xenografts. Cancer Letters, 2019, 456, 29-39.	7.2	41
79	Endogenous glutamine decrease is associated with pancreatic cancer progression. Oncotarget, 2017, 8, 95361-95376.	1.8	41
80	High aspect ratio materials: role of surface chemistry vs. length in the historical â€œlong and short amosite asbestos fibersâ€• Inhalation Toxicology, 2010, 22, 984-998.	1.6	40
81	Self-assembling nanoparticles encapsulating zoledronic acid revert multidrug resistance in cancer cells. Oncotarget, 2015, 6, 31461-31478.	1.8	40
82	IDH2 inhibition enhances proteasome inhibitor responsiveness in hematological malignancies. Blood, 2019, 133, 156-167.	1.4	40
83	Long and short fiber amosite asbestos alters at a different extent the redox metabolism in human lung epithelial cells. Toxicology and Applied Pharmacology, 2003, 193, 106-115.	2.8	39
84	The Role of C/EBP-Î² LIP in Multidrug Resistance. Journal of the National Cancer Institute, 2015, 107, .	6.3	39
85	Light-Regulated NO Release as a Novel Strategy To Overcome Doxorubicin Multidrug Resistance. ACS Medicinal Chemistry Letters, 2017, 8, 361-365.	2.8	39
86	Methotrexate-Loaded Solid Lipid Nanoparticles: Protein Functionalization to Improve Brain Biodistribution. Pharmaceutics, 2019, 11, 65.	4.5	39
87	HIF-1Î± is over-expressed in leukemic cells from TP53-disrupted patients and is a promising therapeutic target in chronic lymphocytic leukemia. Haematologica, 2020, 105, 1042-1054.	3.5	39
88	Coencapsulation of disulfiram and doxorubicin in liposomes strongly reverses multidrug resistance in breast cancer cells. International Journal of Pharmaceutics, 2020, 580, 119191.	5.2	39
89	Zoledronic acid-encapsulating self-assembling nanoparticles and doxorubicin: a combinatorial approach to overcome simultaneously chemoresistance and immunoresistance in breast tumors. Oncotarget, 2016, 7, 20753-20772.	1.8	39
90	The NADPH oxidase inhibitor apocynin induces nitric oxide synthesis via oxidative stress. Toxicology and Applied Pharmacology, 2008, 228, 277-285.	2.8	38

#	Article	IF	Citations
91	A diabetic milieu promotes OCT4 and NANOG production in human visceral-derived adipose stem cells. Diabetologia, 2013, 56, 173-184.	6.3	37
92	Insights in the chemical components of liposomes responsible for P-glycoprotein inhibition. Nanomedicine: Nanotechnology, Biology, and Medicine, 2014, 10, 77-87.	3.3	36
93	Novel ureidopropanamide based N-formyl peptide receptor 2 (FPR2) agonists with potential application for central nervous system disorders characterized by neuroinflammation. European Journal of Medicinal Chemistry, 2017, 141, 703-720.	5.5	36
94	A regulatory microRNA network controls endothelial cell phenotypic switch during sprouting angiogenesis. ELife, 2020, 9, .	6.0	35
95	POTENTIAL TOXICITY OF NONREGULATED ASBESTIFORM MINERALS: BALANGEROITE FROM THE WESTERN ALPS. PART 3: DEPLETION OF ANTIOXIDANT DEFENSES. Journal of Toxicology and Environmental Health - Part A: Current Issues, 2005, 68, 41-49.	2.3	34
96	P-glycoprotein-mediated chemoresistance is reversed by carbonic anhydrase XII inhibitors. Oncotarget, 2016, 7, 85861-85875.	1.8	34
97	Carbonic Anhydrase XII Inhibitors Overcome P-Glycoproteinâ€“Mediated Resistance to Temozolomide in Glioblastoma. Molecular Cancer Therapeutics, 2018, 17, 2598-2609.	4.1	34
98	Structureâ€“Activity Relationships of Triple-Action Platinum(IV) Prodrugs with Albumin-Binding Properties and Immunomodulating Ligands. Journal of Medicinal Chemistry, 2021, 64, 12132-12151.	6.4	34
99	Multifunctional thiosemicarbazones and deconstructed analogues as a strategy to study the involvement of metal chelation, Sigma-2 (Ïƒ2) receptor and P-gp protein in the cytotoxic action: InÂvitro and inÂvivo activity in pancreatic tumors. European Journal of Medicinal Chemistry, 2018, 144, 359-371.	5.5	33
100	Simvastatin and downstream inhibitors circumvent constitutive and stromal cell-induced resistance to doxorubicin in IGHV unmutated CLL cells. Oncotarget, 2015, 6, 29833-29846.	1.8	33
101	Digoxin and ouabain induce P-glycoprotein by activating calmodulin kinase II and hypoxia-inducible factor-1Î± in human colon cancer cells. Toxicology and Applied Pharmacology, 2009, 240, 385-392.	2.8	32
102	Increasing intratumor C/EBP-Î² LIP and nitric oxide levels overcome resistance to doxorubicin in triple negative breast cancer. Journal of Experimental and Clinical Cancer Research, 2018, 37, 286.	8.6	32
103	Zoledronic acid overcomes chemoresistance and immunosuppression of malignant mesothelioma. Oncotarget, 2015, 6, 1128-1142.	1.8	32
104	Mouse hepatocytes and LSEC proteome reveal novel mechanisms of ischemia/reperfusion damage and protection by A2aR stimulation. Journal of Hepatology, 2015, 62, 573-580.	3.7	30
105	Impaired chromaffin cell excitability and exocytosis in autistic Timothy syndrome TS2â€neo mouse rescued by Lâ€type calcium channel blockers. Journal of Physiology, 2019, 597, 1705-1733.	2.9	30
106	ABCA1/ABCB1 Ratio Determines Chemo- and Immune-Sensitivity in Human Osteosarcoma. Cells, 2020, 9, 647.	4.1	30
107	Liposomal Nitrooxy-Doxorubicin: One Step over Caelyx in Drug-Resistant Human Cancer Cells. Molecular Pharmaceutics, 2014, 11, 3068-3079.	4.6	29
108	Antagonists of growth hormone-releasing hormone (GHRH) inhibit the growth of human malignant pleural mesothelioma. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 2226-2231.	7.1	29

#	Article	IF	Citations
109	Wnt/ILâ€1Î²/ILâ€8 autocrine circuitries control chemoresistance in mesothelioma initiating cells by inducing ABCB5. International Journal of Cancer, 2020, 146, 192-207.	5.1	29
110	The heme synthesis-export system regulates the tricarboxylic acid cycle flux and oxidative phosphorylation. Cell Reports, 2021, 35, 109252.	6.4	29
111	POTENTIAL TOXICITY OF NONREGULATED ASBESTIFORM MINERALS: BALANGEROITE FROM THE WESTERN ALPS. PART 2: OXIDANT ACTIVITY OF THE FIBERS. Journal of Toxicology and Environmental Health - Part A: Current Issues, 2005, 68, 21-39.	2.3	28
112	Cycling of NADPH by glucose 6-phosphate dehydrogenase optimizes the spectrophotometric assay of nitric oxide synthase activity in cell lysates. Nitric Oxide - Biology and Chemistry, 2006, 15, 148-153.	2.7	28
113	Nitric oxide and P-glycoprotein modulate the phagocytosis of colon cancer cells. Journal of Cellular and Molecular Medicine, 2011, 15, 1492-1504.	3.6	28
114	Solid lipid nanoparticles by coacervation loaded with a methotrexate prodrug: preliminary study for glioma treatment. Nanomedicine, 2017, 12, 639-656.	3.3	28
115	Cholesterol metabolism: At the cross road between cancer cells and immune environment. International Journal of Biochemistry and Cell Biology, 2020, 129, 105876.	2.8	28
116	Induced expression of P-gp and BCRP transporters on brain endothelial cells using transferrin functionalized nanostructured lipid carriers: A first step of a potential strategy for the treatment of Alzheimerâ€™s disease. International Journal of Pharmaceutics, 2020, 591, 120011.	5.2	28
117	Digoxin and ouabain increase the synthesis of cholesterol in human liver cells. Cellular and Molecular Life Sciences, 2009, 66, 1580-1594.	5.4	27
118	Digoxin and ouabain induce the efflux of cholesterol via liver X receptor signalling and the synthesis of ATP in cardiomyocytes. Biochemical Journal, 2012, 447, 301-311.	3.7	27
119	Doxorubicin-antioxidant co-drugs. Bioorganic and Medicinal Chemistry Letters, 2013, 23, 5307-5310.	2.2	27
120	An Autocrine Cytokine/JAK/STAT-Signaling Induces Kynurenine Synthesis in Multidrug Resistant Human Cancer Cells. PLoS ONE, 2015, 10, e0126159.	2.5	27
121	Fluorescent Nitric Oxide Photodonors Based on BODIPY and Rhodamine Antennae. Chemistry - A European Journal, 2019, 25, 11080-11084.	3.3	26
122	Carbonic Anhydrase XII Inhibitors Overcome Temozolomide Resistance in Glioblastoma. Journal of Medicinal Chemistry, 2019, 62, 4174-4192.	6.4	26
123	Design, Biological Evaluation, and Molecular Modeling of Tetrahydroisoquinoline Derivatives: Discovery of A Potent P-Glycoprotein Ligand Overcoming Multidrug Resistance in Cancer Stem Cells. Journal of Medicinal Chemistry, 2019, 62, 974-986.	6.4	26
124	Loss of C/EBP-Î² LIP drives cisplatin resistance in malignant pleural mesothelioma. Lung Cancer, 2018, 120, 34-45.	2.0	25
125	The SRCIN1/p140Cap adaptor protein negatively regulates the aggressiveness of neuroblastoma. Cell Death and Differentiation, 2020, 27, 790-807.	11.2	25
126	Overcoming multidrug resistance by targeting mitochondria with NO-donating doxorubicins. Bioorganic and Medicinal Chemistry, 2016, 24, 967-975.	3.0	24

#	Article	IF	Citations
127	Rictor/mTORC2 deficiency enhances keratinocyte stress tolerance via mitohormesis. Cell Death and Differentiation, 2017, 24, 731-746.	11.2	24
128	Overcoming Doxorubicin Resistance with Lipidâ€“Polymer Hybrid Nanoparticles Photoreleasing Nitric Oxide. Molecular Pharmaceutics, 2020, 17, 2135-2144.	4.6	24
129	Novel and Selective Fluorescent Ïƒ‹sub›2‹/sub›â€Receptor Ligand with a 3,4â€Dihydroisoquinolinâ€1â€one Scaffold: A Tool to Study Ïƒ‹sub›2‹/sub› Receptors in Living Cells. ChemBioChem, 2015, 16, 1078-1083.	2.6	23
130	Doxorubicin-resistant osteosarcoma: novel therapeutic approaches in sight?. Future Oncology, 2017, 13, 673-677.	2.4	23
131	New Strategies to Overcome Resistance to Chemotherapy and Immune System in Cancer. International Journal of Molecular Sciences, 2019, 20, 4783.	4.1	23
132	New NO- and H2S-releasing doxorubicins as targeted therapy against chemoresistance in castration-resistant prostate cancer: in vitro and in vivo evaluations. Investigational New Drugs, 2018, 36, 985-998.	2.6	22
133	Mitochondrial Delivery of Phenol Substructure Triggers Mitochondrial Depolarization and Apoptosis of Cancer Cells. Frontiers in Pharmacology, 2018, 9, 580.	3.5	22
134	Editorial: Multidrug Resistance in Cancer: Pharmacological Strategies from Basic Research to Clinical Issues. Frontiers in Oncology, 2015, 5, 105.	2.8	21
135	VÎ³9VÎ´2 T Cells in the Bone Marrow of Myeloma Patients: A Paradigm of Microenvironment-Induced Immune Suppression. Frontiers in Immunology, 2018, 9, 1492.	4.8	21
136	Design, synthesis and biological evaluation of stereo- and regioisomers of amino aryl esters as multidrug resistance (MDR) reversers. European Journal of Medicinal Chemistry, 2019, 182, 111655.	5.5	21
137	Asbestos induces doxorubicin resistance in MM98 mesothelioma cells via HIF-1Â. European Respiratory Journal, 2008, 32, 443-451.	6.7	20
138	Inhibition of the mevalonate pathway to override chemoresistance and promote the immunogenic demise of cancer cells. OncoImmunology, 2013, 2, e25770.	4.6	20
139	Unprecedented collateral sensitivity for cisplatin-resistant lung cancer cells presented by new ruthenium organometallic compounds. Inorganic Chemistry Frontiers, 2021, 8, 1983-1996.	6.0	20
140	Metabolic Alterations in a Slow-Paced Model of Pancreatic Cancer-Induced Wasting. Oxidative Medicine and Cellular Longevity, 2018, 2018, 1-10.	4.0	19
141	Insights into P-Glycoprotein Inhibitors: New Inducers of Immunogenic Cell Death. Cells, 2020, 9, 1033.	4.1	19
142	Novel Derivatives of 1-Cyclohexyl-4-[3-(5-methoxy-1,2,3,4-tetrahydronaphthalen-1-yl)propyl]piperazine (PB28) with Improved Fluorescent and Ïƒ Receptors Binding Properties. Journal of Medicinal Chemistry, 2014, 57, 3314-3323.	6.4	18
143	Pro- and anti-oxidant properties of near-infrared (NIR) light responsive carbon nanoparticles. Free Radical Biology and Medicine, 2019, 134, 165-176.	2.9	18
144	Mutant p53 induces SIRT3/MnSOD axis to moderate ROS production in melanoma cells. Archives of Biochemistry and Biophysics, 2020, 679, 108219.	3.0	18

#	Article	IF	Citations
145	NAMPT Over-Expression Recapitulates the BRAF Inhibitor Resistant Phenotype Plasticity in Melanoma. Cancers, 2020, 12, 3855.	3.7	17
146	Nitric oxide synthetic pathway and cGMP levels are altered in red blood cells from end-stage renal disease patients. Molecular and Cellular Biochemistry, 2016, 417, 155-167.	3.1	16
147	ABCA1, apoA-I, and BTN3A1: A Legitimate MÃ©nage Ã Trois in Dendritic Cells. Frontiers in Immunology, 2018, 9, 1246.	4.8	16
148	Sphingolipid Synthesis Inhibition by Myriocin Administration Enhances Lipid Consumption and Ameliorates Lipid Response to Myocardial Ischemia Reperfusion Injury. Frontiers in Physiology, 2019, 10, 986.	2.8	16
149	Applicability and Limitations in the Characterization of Poly-Dispersed Engineered Nanomaterials in Cell Media by Dynamic Light Scattering (DLS). Materials, 2019, 12, 3833.	2.9	16
150	Statins-Mediated Inhibition of Rho GTPases as a Potential Tool in Anti-Tumor Therapy. Mini-Reviews in Medicinal Chemistry, 2008, 8, 609-618.	2.4	15
151	New tetrahydroisoquinoline-based P-glycoprotein modulators: decoration of the biphenyl core gives selective ligands. MedChemComm, 2018, 9, 862-869.	3.4	15
152	VÎ³9VÎ´2 T Cells as Strategic Weapons to Improve the Potency of Immune Checkpoint Blockade and Immune Interventions in Human Myeloma. Frontiers in Oncology, 2018, 8, 508.	2.8	15
153	MRP1-Collateral Sensitizers as a Novel Therapeutic Approach in Resistant Cancer Therapy: An In Vitro and In Vivo Study in Lung Resistant Tumor. International Journal of Molecular Sciences, 2020, 21, 3333.	4.1	15
154	Validation of Thiosemicarbazone Compounds as P-Glycoprotein Inhibitors in Human Primary Brainâ€“Blood Barrier and Glioblastoma Stem Cells. Molecular Pharmaceutics, 2019, 16, 3361-3373.	4.6	14
155	Mitochondrial metabolism: Inducer or therapeutic target in tumor immune-resistance?. Seminars in Cell and Developmental Biology, 2020, 98, 80-89.	5.0	14
156	Design and synthesis of fluorescent ligands for the detection of cannabinoid type 2 receptor (CB2R). European Journal of Medicinal Chemistry, 2020, 188, 112037.	5.5	14
157	Small Nucleolar RNAs Determine Resistance to Doxorubicin in Human Osteosarcoma. International Journal of Molecular Sciences, 2020, 21, 4500.	4.1	14
158	Glabratephrin reverses doxorubicin resistance in triple negative breast cancer by inhibiting P-glycoprotein. Pharmacological Research, 2022, 175, 105975.	7.1	14
159	Simian Virus 40 Infection Down-Regulates the Expression of Nitric Oxide Synthase in Human Mesothelial Cells. Cancer Research, 2004, 64, 4082-4084.	0.9	13
160	New Tetrahydroisoquinoline Derivatives Overcome Pgp Activity in Brain-Blood Barrier and Glioblastoma Multiforme in Vitro. Molecules, 2018, 23, 1401.	3.8	13
161	One molecule two goals: A selective P-glycoprotein modulator increases drug transport across gastro-intestinal barrier and recovers doxorubicin toxicity in multidrug resistant cancer cells. European Journal of Medicinal Chemistry, 2020, 208, 112843.	5.5	13
162	Targeting Mitochondrial Oncometabolites: A New Approach to Overcome Drug Resistance in Cancer. Pharmaceutics, 2021, 13, 762.	4.5	13

#	Article	IF	Citations
163	Atorvastatin modulates anti-proliferative and pro-proliferative signals in Her2/neu-positive mammary cancer. Biochemical Pharmacology, 2011, 82, 1079-1089.	4.4	12
164	Antioxidants Prevent the RhoA Inhibition Evoked by Crocidolite Asbestos in Human Mesothelial and Mesothelioma Cells. American Journal of Respiratory Cell and Molecular Biology, 2011, 45, 625-631.	2.9	12
165	Aceclofenacâ€“Galactose Conjugate: Design, Synthesis, Characterization, and Pharmacological and Toxicological Evaluations. Molecular Pharmaceutics, 2018, 15, 3101-3110.	4.6	12
166	6,7-Dimethoxy-2-phenethyl-1,2,3,4-tetrahydroisoquinoline amides and corresponding ester isosteres as multidrug resistance reversers. Journal of Enzyme Inhibition and Medicinal Chemistry, 2020, 35, 974-992.	5.2	12
167	Targeting HIF-1Î± Regulatory Pathways as a Strategy to Hamper Tumor-Microenvironment Interactions in CLL. Cancers, 2021, 13, 2883.	3.7	12
168	Development of sigma-1 (Ïƒ 1) receptor fluorescent ligands as versatile tools to study Ïƒ 1 receptors. European Journal of Medicinal Chemistry, 2016, 108, 577-585.	5.5	11
169	A Molecular Hybrid for Mitochondriaâ€Targeted NO Photodelivery. ChemMedChem, 2018, 13, 87-96.	3.2	11
170	â€œThree-Bulletsâ€•Loaded Mesoporous Silica Nanoparticles for Combined Photo/Chemotherapy. Nanomaterials, 2019, 9, 823.	4.1	11
171	MRP5 nitration by NO-releasing gemcitabine encapsulated in liposomes confers sensitivity in chemoresistant pancreatic adenocarcinoma cells. Biochimica Et Biophysica Acta - Molecular Cell Research, 2020, 1867, 118824.	4.1	11
172	Calcitriol Inhibits Viability and Proliferation in Human Malignant Pleural Mesothelioma Cells. Frontiers in Endocrinology, 2020, 11, 559586.	3.5	11
173	Multifunctional thiosemicarbazones targeting sigma receptors: in vitro and in vivo antitumor activities in pancreatic cancer models. Cellular Oncology (Dordrecht), 2021, 44, 1307-1323.	4.4	11
174	miRNA-guided reprogramming of glucose and glutamine metabolism and its impact on cell adhesion/migration during solid tumor progression. Cellular and Molecular Life Sciences, 2022, 79, 216.	5.4	11
175	Cholesterol and Its Derivatives: Multifaceted Players in Breast Cancer Progression. Frontiers in Oncology, 0, 12, .	2.8	11
176	Combination of PDT and NOPDT with a Tailored BODIPY Derivative. Antioxidants, 2019, 8, 531.	5.1	10
177	Paracetamolâ€“Galactose Conjugate: A Novel Prodrug for an Old Analgesic Drug. Molecular Pharmaceutics, 2019, 16, 4181-4189.	4.6	10
178	Synthesis of defined oligohyaluronates-decorated liposomes and interaction with lung cancer cells. Carbohydrate Polymers, 2020, 248, 116798.	10.2	10
179	Click ferrocenyl-erlotinib conjugates active against erlotinib-resistant non-small cell lung cancer cells in vitro. Bioorganic Chemistry, 2022, 119, 105514.	4.1	10
180	TFEB controls integrin-mediated endothelial cell adhesion by the regulation of cholesterol metabolism. Angiogenesis, 2022, 25, 471-492.	7.2	10

#	Article	IF	Citations
181	Tuning the Hydrophobicity of a Mitochondriaâ€Targeted NO Photodonor. ChemMedChem, 2018, 13, 1238-1245.	3.2	9
182	Impact of ABC Transporters in Osteosarcoma and Ewingâ€™s Sarcoma: Which Are Involved in Chemoresistance and Which Are Not?. Cells, 2021, 10, 2461.	4.1	9
183	Calcium Phosphate-Coated Lipid Nanoparticles as a Potential Tool in Bone Diseases Therapy. Nanomaterials, 2021, 11, 2983.	4.1	9
184	Electronic Coupling in 1,2,3-Triazole Bridged Ferrocenes and Its Impact on Reactive Oxygen Species Generation and Deleterious Activity in Cancer Cells. Inorganic Chemistry, 2022, 61, 9650-9666.	4.0	9
185	Plant-Derived Trans-Î²-Caryophyllene Boosts Glucose Metabolism and ATP Synthesis in Skeletal Muscle Cells through Cannabinoid Type 2 Receptor Stimulation. Nutrients, 2021, 13, 916.	4.1	8
186	ÎºBÎ± targeting promotes oxidative stress-dependent cell death. Journal of Experimental and Clinical Cancer Research, 2021, 40, 136.	8.6	8
187	HSD17B7 gene in selfâ€renewal and oncogenicity of keratinocytes from Black versus White populations. EMBO Molecular Medicine, 2021, 13, e14133.	6.9	8
188	Tuning NO release of organelle-targeted furoxan derivatives and their cytotoxicity against lung cancer cells. Bioorganic Chemistry, 2021, 111, 104911.	4.1	8
189	Nitroarginine methyl ester and canavanine lower intracellular reduced glutathione. Free Radical Biology and Medicine, 2003, 35, 1210-1216.	2.9	7
190	Asbestos Induces Nitric Oxide Synthesis in Mesothelioma Cells via Rho Signaling Inhibition. American Journal of Respiratory Cell and Molecular Biology, 2007, 36, 746-756.	2.9	7
191	Treatment with ROS detoxifying gold quantum clusters alleviates the functional decline in a mouse model of Friedreich ataxia. Science Translational Medicine, 2021, 13, .	12.4	7
192	Targeted Self-Emulsifying Drug Delivery Systems to Restore Docetaxel Sensitivity in Resistant Tumors. Pharmaceutics, 2022, 14, 292.	4.5	7
193	SKP2 drives the sensitivity to neddylation inhibitors and cisplatin in malignant pleural mesothelioma. Journal of Experimental and Clinical Cancer Research, 2022, 41, 75.	8.6	7
194	A Biomonitoring Pilot Study in Workers from a Paints Production Plant Exposed to Pigment-Grade Titanium Dioxide (TiO2). Toxics, 2022, 10, 171.	3.7	7
195	Doxorubicin-Loaded Lipid Nanoparticles Coated with Calcium Phosphate as a Potential Tool in Human and Canine Osteosarcoma Therapy. Pharmaceutics, 2022, 14, 1362.	4.5	7
196	Solid Lipid Nanoparticles Loaded with Antitumor Lipophilic Prodrugs Aimed to Glioblastoma Treatment: Preliminary Studies on Cultured Cells. Journal of Nanoscience and Nanotechnology, 2017, 17, 3606-3614.	0.9	6
197	Comparison of Allogeneic and Syngeneic Rat Glioma Models by Using MRI and Histopathologic Evaluation. Comparative Medicine, 2017, 67, 147-156.	1.0	6
198	Overcoming Multidrug Resistance (MDR): Design, Biological Evaluation and Molecular Modelling Studies of 2,4â€Substituted Quinazoline Derivatives. ChemMedChem, 2022, 17, .	3.2	6

#	Article	IF	Citations
199	Joining European Scientific Forces to Face Pandemics. Trends in Microbiology, 2021, 29, 92-97.	7.7	5
200	Efficacy, biocompatibility and degradability of carbon nanoparticles for photothermal therapy of lung cancer. Nanomedicine, 2021, 16, 689-707.	3.3	5
201	In vitro vascular toxicity assessment of NitDOX, a novel NO-releasing doxorubicin. European Journal of Pharmacology, 2020, 880, 173164.	3.5	5
202	Endothelial Heme Dynamics Drive Cancer Cell Metabolism by Shaping the Tumor Microenvironment. Biomedicines, 2021, 9, 1557.	3.2	5
203	Ketogal Safety Profile in Human Primary Colonic Epithelial Cells and in Mice. Pharmaceuticals, 2021, 14, 1149.	3.8	5
204	Inhibition of Heme Export and/or Heme Synthesis Potentiates Metformin Anti-Proliferative Effect on Cancer Cell Lines. Cancers, 2022, 14, 1230.	3.7	5
205	New Pharmacological Strategies against Pancreatic Adenocarcinoma: The Multifunctional Thiosemicarbazone FA4. Molecules, 2022, 27, 1682.	3.8	5
206	Sound-based assembly of a microcapillary network in a saturn-like tumor model for drug testing. Materials Today Bio, 2022, 16, 100357.	5.5	5
207	Evaluation of the Preclinical Efficacy of Lurbinectedin in Malignant Pleural Mesothelioma. Cancers, 2021, 13, 2332.	3.7	4
208	Sdox, a H2S releasing anthracycline, with a safer profile than doxorubicin toward vasculature. Vascular Pharmacology, 2022, 143, 106969.	2.1	4
209	Splicing deregulation, microRNA and notch aberrations: fighting the three-headed dog to overcome drug resistance in malignant mesothelioma. Expert Review of Clinical Pharmacology, 2022, 15, 305-322.	3.1	4
210	Identification of Redox-Sensitive Transcription Factors as Markers of Malignant Pleural Mesothelioma. Cancers, 2021, 13, 1138.	3.7	3
211	Transcriptional perturbation of protein arginine methyltransferase-5 exhibits MTAP-selective oncosuppression. Scientific Reports, 2021, 11, 7434.	3.3	3
212	Overcoming drug resistance in glioblastoma: new options in sight?. , 2021, 4, 512-516.		3
213	Endothelial Cells Promote Osteogenesis by Establishing a Functional and Metabolic Coupling With Human Mesenchymal Stem Cells. Frontiers in Physiology, 2021, 12, 813547.	2.8	3
214	A Comprehensive Evaluation of Sdox, a Promising H2S-Releasing Doxorubicin for the Treatment of Chemoresistant Tumors. Frontiers in Pharmacology, 2022, 13, 831791.	3.5	3
215	Mitochondrial metabolic alterations in cancer cells and related therapeutic targets. Seminars in Cell and Developmental Biology, 2020, 98, 1-3.	5.0	2
216	Predialysis and Dialysis Therapies Differently Affect Nitric Oxide Synthetic Pathway in Red Blood Cells from Uremic Patients: Focus on Peritoneal Dialysis. International Journal of Molecular Sciences, 2021, 22, 3049.	4.1	2

#	Article	IF	Citations
217	IL17A Depletion Affects the Metabolism of Macrophages Treated with Gemcitabine. Antioxidants, 2021, 10, 422.	5.1	2
218	Micro-RNA-215 and -375 regulate thymidylate synthase protein expression in pleural mesothelioma and mediate epithelial to mesenchymal transition. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2022, , 1.	2.8	1
219	Rho-GTPases and Statins: A Potential Target and a Potential Therapeutic Tool Against Tumors?. , 2014, , 209-245.		0
220	1601dâ€…Hazard determinants of carbon nanotubes (cnts) driving molecular initiating events (mies) in adverse outcome pathways (aops) of airways diseases. , 2018, , .		0
221	IH2 INHIBITION ENHANCES PROTEASOME INHIBITOR RESPONSIVENESS IN HEMATOLOGICAL MALIGNANCIES. Hematological Oncology, 2019, 37, 515-515.	1.7	0
222	The Hypoxia-Inducible Factor-1alpha Is Constitutively Upregulated in TP53 Disrupted CLL Cells: A Potential Target to Overcome Fludarabine Resistance. Blood, 2015, 126, 2925-2925.	1.4	0
223	ATP-Binding-Cassette A1 Regulates Extracellular Isopentenyl Pyrophosphate Release and VÎ³9VÎ´2 T-Cell Activation By Dendritic Cells. Blood, 2016, 128, 3709-3709.	1.4	0
224	HIF-1Î± Upregulation in TP53 Disrupted Chronic Lymphocytic Leukemia Cells and Its Potential Role As a Therapeutic Target. Blood, 2016, 128, 305-305.	1.4	0
225	Selinexor in Combination with Chemotherapy or Idelalisib Elicits a Synergistic Cytotoxic Effect in Primary CLL Cells, Also Overcoming Intrinsic and Stromal Cells-Mediated Fludarabine Resistance. Blood, 2016, 128, 3210-3210.	1.4	0
226	Nitric Oxide Reinstates Doxorubicin Cytotoxic and Proimmunogenic Effects in Refractory Breast Cancer. , 2019, , 325-326.		0